Neuren Pharmaceuticals Limited (NEU.AX)
ASX · AUD · Healthcare · Biotechnology
A$18.70 (+0.27%) as of
Key statistics
- Market cap
- 2.37B
- P/E (TTM)
- 124.67
- Forward P/E
- 31.34
- EPS (TTM)
- 0.15
- Dividend yield
- 1.61%
- 52-week range
- 11.00 – 23.76
- Beta
- 1.57
- Revenue (TTM)
- 69.53M
- Profit margin
- 29.14%
- Analyst target
- A$25.91
- Volume
- 445.65k
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hawthorn East, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.